Jennifer Louie

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background: Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient's own immune system to increase anti-tumor activity. While immunocheckpoint blockade has shown promising results, only 20–40 % of patients(More)
  • 1